- Research works
- 52 ▲ 53% vs 2013–17
- Citations
- 880 17.0 per fractional work
- Top-10% rate
- 18.5% record average 16.5%
- Open access
- 19% world 28%
Not ranked overall: Groupe Francophone des Myélodysplasies is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Decision Sciences, 5.0×. Every wedge is a field page.
Which keywords describe research at Groupe Francophone des Myélodysplasies?
By fractional works in all years, weighted toward what it does more of than the world: Prognostic Factors, Hematopoietic Stem Cells, Acute Myeloid Leukemia, AML, Rituximab, Therapeutic Targets, Minimal Residual Disease and Chronic Lymphocytic Leukemia.
- Hemostasis
- Antiretroviral Therapy
- Primary Immunodeficiency
- Guidelines
- Bone Marrow Niche
- Childhood Cancer
- Acute Lymphoblastic Leukemia
- Thalassemia
- Blood Groups
- Pancreatic Cancer
- Treatment
- Anemia
- JAK2 Mutation
- Proteasome Inhibitors
- Diagnosis Criteria
- Epidemiology
- Chronic Lymphocytic Leukemia
- Minimal Residual Disease
- Acute Myeloid Leukemia
- Hematopoietic Stem Cells
- Prognostic Factors
- AML
- Rituximab
- Therapeutic Targets
- Genomic Aberrations
- Inflammation
- International Myeloma Working Group
- Prognostic Scoring System
- Myelofibrosis
- Diagnosis
- Genetic Mutations
- Alloimmunization
- Sickle-cell Disease
- Mutation
- BCR-ABL
- Imatinib
- Graft-versus-Host Disease
- Immune Dysregulation
- Thrombosis
- Cognitive Impairment
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Prognostic Factors15▲ 64×5 topics
- Hematopoietic Stem Cells11▲ 202×3 topics
- AML9▲ 363×1 topic
- Acute Myeloid Leukemia9▲ 363×1 topic
- Rituximab5▲ 61×3 topics
- Minimal Residual Disease5▲ 132×2 topics
- Therapeutic Targets5▲ 37×2 topics
- Chronic Lymphocytic Leukemia4▲ 176×1 topic
- Genomic Aberrations4▲ 176×1 topic
- Epidemiology4▲ 2.0×15 topics
- Inflammation4▲ 3.0×19 topics
- Diagnosis Criteria3▲ 196×1 topic
- International Myeloma Working Group3▲ 196×1 topic
- Proteasome Inhibitors3▲ 86×2 topics
- Prognostic Scoring System3▲ 153×2 topics
- JAK2 Mutation3▲ 254×1 topic
- Myelofibrosis3▲ 254×1 topic
- Anemia2▲ 39×3 topics
- Diagnosis2▲ 4.4×12 topics
- Treatment2▲ 3.2×11 topics
- Genetic Mutations2▲ 7.1×3 topics
- Pancreatic Cancer2▲ 30×2 topics
- Alloimmunization2▲ 92×1 topic
- Blood Groups2▲ 92×1 topic
- Sickle-cell Disease2▲ 73×1 topic
- Thalassemia2▲ 73×1 topic
- Mutation2▲ 19×2 topics
- Acute Lymphoblastic Leukemia2▲ 79×1 topic
- BCR-ABL2▲ 106×1 topic
- Childhood Cancer2▲ 79×1 topic
- Imatinib2▲ 106×1 topic
- Bone Marrow Niche1▲ 73×1 topic
- Graft-versus-Host Disease1▲ 73×1 topic
- Guidelines1▲ 5.1×7 topics
- Immune Dysregulation1▲ 30×1 topic
- Primary Immunodeficiency1▲ 61×1 topic
- Thrombosis1▲ 11×4 topics
- Antiretroviral Therapy1▲ 9.5×2 topics
- Cognitive Impairment1▲ 8.6×2 topics
- Hemostasis1▲ 13×2 topics
Which research topics does Groupe Francophone des Myélodysplasies publish most on?
By volume in 2022–2025: Acute Myeloid Leukemia Research, Enhanced Recovery After Surgery, Clinical practice guidelines implementation and Meta-analysis and systematic reviews.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Acute Myeloid Leukemia Research Hematology 1 works
- 2 Enhanced Recovery After Surgery Surgery 0 works
- 3 Clinical practice guidelines implementation Public Health, Environmental and Occupational Health 0 works
- 4 Meta-analysis and systematic reviews Statistics, Probability and Uncertainty 0 works
- 5 Chronic Myeloid Leukemia Treatments Hematology 0 works
- 6 Lepidoptera: Biology and Taxonomy Genetics 0 works
- 7 Minimally Invasive Surgical Techniques Surgery 0 works
- 8 Appendicitis Diagnosis and Management Emergency Medicine 0 works
- 9 Abdominal Surgery and Complications Pulmonary and Respiratory Medicine 0 works
- 10 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Groupe Francophone des Myélodysplasies's research output changed?
Output in 2018–2022 was 53% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Paris
- Centre National de la Recherche Scientifique
- Inserm
- Sorbonne Université
- Université Paris Cité
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives
- Université Paris 1 Panthéon-Sorbonne
- Institut Pasteur
- Assistance Publique – Hôpitaux de Paris
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.